{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:40:06Z","timestamp":1744666806680,"version":"3.40.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:p>This study evaluates the short-term effects of rivaroxaban combined with aspirin in treating lower limb arterial atherosclerosis occlusion after stent placement. Between July 2018 and December 2022, 141 patients with lower limb arterial atherosclerosis occlusion underwent stent placement and were divided into 2 groups based on the different treatments documented in the cases. The clopidogrel group (n\u2005=\u200570) received clopidogrel sulfate plus aspirin, while the rivaroxaban group (n\u2005=\u200571) received rivaroxaban plus aspirin. Outcomes included 1-year patency rate, bleeding events, acute embolism, amputation rates, coagulation indicators, and thromboelastography (TEG) parameters. The 1-year patency rate at 6 months postoperatively was higher in the rivaroxaban group (92.96%) compared to the clopidogrel group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Both groups showed increased activated partial thromboplastin time (APTT) and prothrombin time (PT) and decreased D-dimer (D-D) and fibrinogen (FIB) levels after 6 months (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). APTT and PT were higher, while D-D and FIB were lower in the rivaroxaban group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). TEG parameters showed increased reaction time (R), clot formation time (K), and clot index (CI) and decreased alpha angle (\u03b1), maximum amplitude (MA), and thromboelastometry (G) in both groups at 6 months. R, K, and CI were higher, and \u03b1, MA, and G were lower in the rivaroxaban group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Bleeding events were similar between groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05), with 1 embolism case in the rivaroxaban group vs 2 in the clopidogrel group. Rivaroxaban combined with aspirin post-stent placement improved vascular patency and anticoagulation outcomes without increasing bleeding risk, offering an effective treatment option for lower limb arterial atherosclerosis occlusion.<\/jats:p>","DOI":"10.1097\/md.0000000000042147","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:00:07Z","timestamp":1744664407000},"page":"e42147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-term effects of rivaroxaban combined with aspirin in the treatment of lower limb arterial atherosclerosis occlusion with stent placement: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Jian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanjun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5972-0357","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Wuhan No.1 Hospital, Wuhan, Hubei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250414","first-page":"961","article-title":"Progress and prospect of the treatment of lower extremity arteriosclerosis obliterans.","volume":"59","author":"Zheng","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"R2-20250414","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3233\/THC-230256","article-title":"Effect of hydration therapy and nursing intervention on preventing contrast-induced nephropathy after interventional treatment of lower extremity arteriosclerosis obliterans.","volume":"32","author":"Chen","year":"2024","journal-title":"Technol Health Care"},{"key":"R3-20250414","doi-asserted-by":"crossref","first-page":"e3685","DOI":"10.1002\/cnm.3685","article-title":"Patient-specific finite element simulation of peripheral artery percutaneous transluminal angioplasty to evaluate the procedure outcome without stent implantation.","volume":"39","author":"Helou","year":"2023","journal-title":"Int J Numer Method Biomed Eng"},{"key":"R4-20250414","doi-asserted-by":"crossref","first-page":"1039313","DOI":"10.3389\/fcvm.2022.1039313","article-title":"Protocol of the evolution study: a prospective, multicenter, observational study evaluating the effect and health economics of endovascular treatment in patients with moderate and severe calcification of femoropopliteal artery.","volume":"9","author":"Pan","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R5-20250414","first-page":"186","article-title":"Progress in endovascular treatment of arteriosclerosis obliterans of lower limbs.","volume":"15","author":"Ainiwazulikai","year":"2023","journal-title":"China J Vasc Surg"},{"key":"R6-20250414","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1532\/hsf.5303","article-title":"Systemic immune-inflammation index predicts restenosis after interventions for lower extremity arteriosclerosis obliterans.","volume":"26","author":"Tian","year":"2023","journal-title":"Heart Surg Forum"},{"key":"R7-20250414","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.21037\/apm-22-827","article-title":"Effect of diabetes on the prognosis, serum inflammatory factors, and quality of life of patients with lower extremity arteriosclerosis obliterans after vascular intervention: a retrospective comparative cohort study.","volume":"11","author":"Zhao","year":"2022","journal-title":"Ann Palliat Med"},{"key":"R8-20250414","doi-asserted-by":"crossref","first-page":"e4945","DOI":"10.1161\/CIRCOUTCOMES.118.004945","article-title":"Tailoring antiplatelet therapy intensity to ischemic and bleeding risk.","volume":"12","author":"Baber","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R9-20250414","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s40265-020-01397-7","article-title":"Rivaroxaban: a review for secondary cv prevention in CAD and PAD.","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"R10-20250414","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease.","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"R11-20250414","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/15266028221092979","article-title":"Safety and effectiveness of excimer laser ablation combined with drug-coated balloon for atherosclerotic obliterans in the lower extremity.","volume":"30","author":"Jiang","year":"2023","journal-title":"J Endovasc Ther"},{"key":"R12-20250414","first-page":"669","article-title":"China expert consensus on diagnosis and treatment of femoral-popliteal artery occlusion","volume":"37","year":"2022","journal-title":"China Circ J"},{"key":"R13-20250414","first-page":"555","article-title":"Correlation between serum miR-140-5p and in-stent restenosis after stent implantation in patients with arteriosclerosis obliterans of lower limbs","volume":"31","author":"Zhang","year":"2022","journal-title":"J Interventional Radiol"},{"key":"R14-20250414","first-page":"9","article-title":"The correlation between the levels of serum endothelin -1, nitric oxide and C-reactive protein and restenosis after stent implantation in arteriosclerosis obliterans of lower limbs","volume":"26","author":"Li","year":"2022","journal-title":"J Clin Med Pract"},{"key":"R15-20250414","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/2311-8571.373586","article-title":"Effect of herb-partitioned moxibustion on structure and functional prediction of gut microbiota in rats with irritable bowel syndrome with diarrhea.","volume":"9","author":"Liu","year":"2023","journal-title":"World J Tradit Chin Med"},{"key":"R16-20250414","first-page":"3209","article-title":"Study on the effect of rivaroxaban and clopidogrel combined antithrombotic in patients with acute coronary syndrome complicated with atrial fibrillation after PCI.","volume":"42","author":"Bai","year":"2020","journal-title":"Hebei Med"},{"key":"R17-20250414","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1124\/jpet.122.001222","article-title":"Identification of infigratinib as a potent reversible inhibitor and mechanism-based inactivator of CYP2J2: nascent evidence for a potential in vivo metabolic drug-drug interaction with rivaroxaban.","volume":"382","author":"Tang L","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-20250414","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","article-title":"The first 3500 years of aspirin history from its roots \u2013 a concise summary.","volume":"113","author":"Montinari","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"R19-20250414","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization.","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"R20-20250414","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease.","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T21:00:12Z","timestamp":1744664412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":20,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042147","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}